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Neuroendocrine lung cancer (NELC) represents 25% of all lung cancer cases and large
patient collectives exist as formalin-fixed, paraffin-embedded (FFPE) tissue only. FFPE is
controversially discussed as source for molecular biological analyses and reference genes
for NELC are poorly establishes.
Material and methods
Forty-three representative FFPE-specimens were used for mRNA expression analysis
using the digital nCounter technology (NanoString). Based on recent literature, a total of 91
mRNA targets were investigated as potential tumor markers or reference genes. The geN-
orm, NormFinder algorithms and coefficient of correlation were used to identify the most
stable reference genes. Statistical analysis was performed by using the R programming
environment (version 3.1.1)
Results
RNA integrity (RIN) ranged from 1.8 to 2.6 and concentrations from 34 to 2,109 ng/μl. How-
ever, the nCounter technology gave evaluable results for all samples tested. ACTB,
CDKN1B, GAPDH, GRB2, RHOA and SDCBP were identified as constantly expressed
genes with high stability (M-)values according to geNorm, NormFinder and coefficients of
correlation.
PLOS ONE | DOI:10.1371/journal.pone.0165181 November 1, 2016 1 / 11
a11111
OPENACCESS
Citation: Walter RFH, Werner R, Vollbrecht C,
Hager T, Flom E, Christoph DC, et al. (2016) ACTB,
CDKN1B, GAPDH, GRB2, RHOA and SDCBP Were
Identified as Reference Genes in Neuroendocrine
Lung Cancer via the nCounter Technology. PLoS
ONE 11(11): e0165181. doi:10.1371/journal.
pone.0165181
Editor: Giancarlo Troncone, Universita degli Studi
di Napoli Federico II, ITALY
Received: July 21, 2016
Accepted: October 8, 2016
Published: November 1, 2016
Copyright: © 2016 Walter et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: For PA Please
request for contact info for additional data. All
relevant data are within the paper and its
Supporting Information files. Ethical concerns
preclude publication of clinical and pahtological
data. To prevent conclusion on individuals
investigated, only pure expression data and tumor
type can be published. We try to avoid releasing
information about age of the patient, patient ID,
year of treatment etc. as stated in the ethic’s
approval of the Ethics Committee of the University
Conclusion
FFPE-derived mRNA is suitable for molecular biological investigations via the nCounter
technology, although it is highly degraded. ACTB, CDKN1B, GAPDH, GRB2, RHOA and
SDCBP are potent reference genes in neuroendocrine tumors of the lung.
Introduction
Neuroendocrine lung cancer (NELC) represents 25% of all lung cancer cases and is divided
into four subgroups (typical (TC) and atypical carcinoids (AC), large- (LCNEC) and small-cell
(neuroendocrine) cancer (SCLC)) [1].
The majority of these clinical samples are stored as formalin-fixed, paraffin-embedded
(FFPE) tissue. FFPE samples can be stored at ambient temperature with minimal logistical
effort and costs. The main disadvantage of formalin fixation is the degradation and alteration
of nucleic acids by oxidative deamination and cross-linking [2–4]. Besides, temperature shifts,
ultraviolet light and reactive oxygen species have a negative impact on nucleic acid stability
and integrity [4] leading to highly degraded nucleic acids. Storage of fresh-frozen tissue may
help to overcome the mentioned problems, but the costs are high and biobanking is in the early
stages of development. An ideal method for the investigation of FFPE is the nCounter technol-
ogy fromNanoString. The technology enables the detection of short target regions (~100 nt)
making it an ideal method for analyzing fragmented nucleic acids from FFPE tissue. Fragments
of 100 nt were reported to be detectable with nearly 100% efficiency [3, 5–7]. Reis et al. com-
pared FFPE versus fresh-frozen samples using the nCounter technique and reported a high
comparability of the results [3]. Very short regions of approximately 100 nt are targeted by two
specific oligo probes that hybridize to the region of interest [6, 8] without any enzymatic step,
hence overcoming limitation of other methods (e.g. PCR), which suffer from enzymatic alter-
ations such as amplification efficiencies [9, 10]. Fluorescent barcodes allow for a simulations
detection of up to 800 different targets per sample [6, 8]. To compensate for technical or bio-
logical variations, normalization of the raw data should be performed. So far, reference gene
normalization seemed to be the best choice for quantitative mRNA analysis, although alterna-
tive quantification/normalization methods are under discussion: These alternatives include
standardization to cell number and RNA mass quantification (most frequently used in North-
ern Blot analysis), but these methods are hardly applicable for clinical samples with low RNA
quality and unknown cell content [9]. Hence, identification of reference genes is need.
But detectable and reliable expression levels as well as robustness of potential reference
genes are discussed controversially, because expression is disease- and tissue-type dependent
[9, 11]. Using inappropriate internal references can have a drastic impact as it can lead to errors
in data acquisition and analysis [10].
Based on recent literature, a custom CodeSet for expression profiling in NELC was designed
and tested on the nCounter platform. To identify potent reference genes in neuroendocrine
lung cancer, two common algorithms (geNorm and NormFinder) were applied. Here we pres-
ent reliable reference genes in NELC that enable a proper normalization, which builds the fun-
dament for good quality data and provides the basis for research approaches such as biomarker
detection.
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Material and Methods
Representative samples of each tumor subtype (15 TC, 9 AC, 7 LCNEC and 12 SCLC) were
used for the mRNA expression analysis using the nCounter platform (NanoString Technolo-
gies, Seattle, WA, USA). Specimens from 2005 till 2012 were taken from the tumor bank at the
Institute of Pathology, University Hospital Essen, University Duisburg-Essen (Germany).
Tumor classification was performed according to theWHO Classification Of Tumours guide-
lines (2004) [12] and TNM-staging was based on theUICC Classification of Malignant
Tumours [13]. The study was conducted retrospectively for the identification of potential
tumor markers and reference genes. The study was approved by the ethical committee of the
University Hospital Essen (ID: 13-5382-BO) and conforms to the principles outlined in the
declaration of Helsinki.
RNA Isolation and RNA Integrity Assessment
Three to five paraffin sections with a thickness of 4 μm per sample were deparaffinizedwith
xylene prior to RNA extraction using the RNeasy FFPE kit (Qiagen, Hilden, Germany) accord-
ing to the manufacturer’s recommendations with slight adjustments as described earlier [14,
15]. Total RNA concentrations were measured using a Nanodrop 1000 instrument (Thermo
Fisher Scientific,Waltham, USA) and an Agilent 2100 Bioanalyzer (eukaryote total RNA
Nano, version 2.6, Agilent Technologies, Santa Clara, USA). RNA integrity was assessed using
the Agilent 2100 bioanalyzer.
nCounter CodeSet Design and Expression Analysis
Multiple genes involved in tumor-associated pathways and neuroendocrinedifferentiation
were included in a custom CodeSet using the standard chemistry. The CodeSetwas designed to
contain a total of 91 genes with different signature genes for each subgroup as described else-
where [7, 14–16]. The CodeSetwas designed and synthesized at NanoString Technologies,
Seattle, USA (S1 Table for properties of the CodeSet).Total RNA (100 ng) including miRNA
was analyzed at the NanoString nCounter Core Facility at the University of Heidelberg,
Germany.
nCounter Data Processing and Statistical Analysis
For each gene, raw NanoString counts were subjected to a technical background correction.
Therefore, the average of the negative controls counts plus two-times the standard deviation
was calculated and subtracted from each target count. Afterwards, either the geNorm or Norm-
Finder algorithmwas used to calculate the gene expression stability measure (M-value) for all
tested genes. In brief, the M-value of a certain gene, calculated by the geNorm algorithm, is the
arrhythmic mean of all pairwise variations of potential control genes [9]. The NormFinder
algorithm estimates a) the intra- and inter-sample variation leading to a distribution, which is
then b) transformed to a one-dimensional value by defining a value of the mean plus one stan-
dard deviation [17]. Genes with average and median counts below 500 were not considered as
potential reference genes, becausemean and median counts<500 indicate that a fraction of
the samples present with absent expression for a certain gene. All statistical and graphical anal-
yses were performed using the R statistical programming environment (v 3.1.1). For dichoto-
mous factors such as gender and expression level the Wilcoxon Mann-Whitney rank sum test
was applied. The Kruskal-Wallis test was used to correlate tumor type and gene expression.
Correlations between gene expression and TNM-stages were analyzed by Spearman’s rank cor-
relation test. Scatterplots were generated and coefficients of determination (R2) were calculated
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for pairwise comparison of potential reference genes. As control, two previously identified
tumor markers (CDK6 and TYMS [14, 15]) were correlated with the reference genes as
described above.
The level of statistical significancewas defined as p0.05.
Results
Forty-three tumor samples were investigated (16 TC (27%) and 13 AC (22%), 16 LCNEC
(27%) and 15 SCLC (25%)). Twenty-five female (58%) and 16 male patients (37%) were ana-
lyzed. For two patients the gender remained inconclusive after anonymization.
RNA integrity (RIN) ranged from 1.8 to 2.6 and concentrations from 34 to 2,109 ng/μl.
Although RIN was considerably low, all tested specimens gave evaluable results with respect to
the nCounter expression analysis. Representative results are summarized in S2 Table. Besides,
Fig 1A and 1B presents exemplary data of the smear analysis.
The NormFinder algorithm identified the following genes as most stably expressed:GRB2
(M-value = 0.422), CDKN1B (M-value = 0.4787),GAPDH (M-value = 0.5228), SDCBP (M-
value = 0.6232), PNN (M-value = 0.6563) and ACTB (M-value = 0.6646).
Whereas, the geNorm algorithm identified these stable reference genes:CDKN1B (M-
value = 4.45),GRB2 (M-value = 4.45), RHOA (M-value = 4.48), SDCBP (M-value = 4.45),
GAPDH (M-value = 4.58) and LDHB (M-value = 4.59).
With respect to the 20 most stable reference genes identified by both algorithms, a consen-
sus for 17 genes (85%) was found. The results for mean and median expression as well as M-
values for both algorithms are summarized in S3 Table.
Statistical analysis for TNM-criteria revealed significant correlations of tumor type and
gene expression of ACTB (p = 0.016), CAT (p = 0.041), LDHB (p = 0.024) and SDCBP
Fig 1. A and B show gel-smear analysis to assess the RNA quantity and quality (RIN) in total RNA
derived from formalin-fixed, paraffin-embedded tissue. Fig 1A depicts a representative smear gel
analysis of twelve samples. A ladder was included to allow size calculation. The microfluid analysis shows
that RNA from FFPE is highly degraded giving no distinct size patterns.Fig 1B depicts the electropherogram
of two representative samples. The rRNA Ratio (28s/18s) is used to calculate the RNA quality according to
an algorithm supplied by the manufacturer. Neither 28s nor 18s bands can be found for FFPE-derived RNA
leading to considerably low RNA integrity numbers (RIN). RNA concentration is calculated from the area
under the curve.
doi:10.1371/journal.pone.0165181.g001
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(p = 0.044), which would render insignificant after a multivariate analysis correction
(e.g. Bonferroni correction or false discovery rate adjustment (FDR)) (S1 Fig). Similarly,
LDHB (p = 0.023) and PNN (p = 0.0.44) were significantly associated with grade of the tumor
(data not shown). For age of the FFPE sample and gender no significant correlations were
noted.
After identification of the six most stable reference genes for each algorithm, the coefficient
of determination (R2) was generated for ACTB, CDKN1B,GAPDH, GRB2, LDHB, PNN, RHOA
and SDCBP. Considering the top-10 of the R2-values,GRB2 (5 times), RHOA (4 times),ACTB
(3 times),GAPDH (3 times) and SDCBP (3 times) showed the highest correlation frequency.
CDKN1B and PNN showed only one correlation with another gene. Then a correlation matrix
was created that confirmed the previous results and also identifiedCDKN1B to have a consid-
erable correlation with GRB2 and GAPDH expression (Fig 2A).
As control, correlation of potential reference gene and suspected tumor markers (CDK6 and
TYMS) was performed revealing very low R2-values, as expected. The R2-values and top-10
ranking are summarized in Table 1. Fig 2A–2C depicts the correlation matrix, a heat map and
two exemplary scatterplots of the correlation analysis. The scatterplots for all gene correlations
are summarized in S2 Fig.
Taking the presented results into consideration,ACTB, CDKN1B,GAPDH, GRB2, RHOA
and SDCBP can be considered as reliable and stably expressed reference genes in neuroendo-
crine lung cancer.
Discussion
Degradation of nucleic acids in FFPE tissue leads to highly degradedRNA and represents an
eminent problem for routine diagnostic and research. Formalin fixation leads to RNA integrity
numbers<3 [18]. Nevertheless, a large proportion of RNA fragments of100 nt remain intact
and can be detected reliably [2, 5]. This fragment length is sufficient to analyze such samples
with the nCounter technology, which uses probe pairs binding to ~100 nt of the target regions
[3, 5–7]. This approach makes it an ideal method for the analysis of degraded archival FFPE tis-
sue. In the present study, we were able to specifically and sensitively analyze 91 mRNA-target
transcripts in 43 FFPE samples by using 100 ng of total RNA per sample. Tumor specimens
from 2005 till 2012 were investigated and age of the FFPE sample did not show a statistically
significant influence on the results.
Housekeeping genes are no longer referred to as reliable reference genes for normalization
[9–11]. For several reference genes the expression is tissue- and disease-specific, therefore lead-
ing to heterogeneous ratings and controversial discussions which genes are suitable as internal
references [9–11]. According to our results, NormFinder [17] and/or geNorm [9] algorithms
plus calculation of the coefficient of determination and matrix correlation identifiedACTB,
CDKN1B,GAPDH, GRB2, RHOA and SDCBP to be reliable and stably expressed reference
genes in neuroendocrine lung cancer. ACTB and GAPDH were detectable in 100% of cases and
the remaining genes were detected in all but one case. As control, the coefficient of determina-
tion was also calculated for the reference genes and tumor markers CDK6 [15] and TYMS [14]
and showed considerably low correlations between them.
A shortcoming of both algorithms is that they prefer low counts over high counts. Higher
counts may lead to a considerably higher deviation. Therefore, very low counts (mean and
median<500 mRNA counts) result in M-values indicating high stability/constant expression.
But in fact, most of the genes identified as stably expressed ones showed very low counts in the
majority of cases (S3 Table). ACTB and GAPDH gave high counts in all samples, but showed a
higher variability. This leads to slightly weaker stability values than found for low expressed
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genes. Still,ACTB and GAPDH can be considered reliable reference genes due to the ubiquitous
and quiet stable expression as well as high-rankedM-values.
To overcome the limitations of both algorithms, calculation of the coefficient of determina-
tion was performed and a correlation matrix was created. The additional tests showed that the
six identified reference genes have a high conformity with respect to their expression profiles.
Usage of multiple robustly expressed internal references is highly encouraged, because a single
reference could lead to false-negative/-positive results due to varying expression [10, 11].
Fig 2. A to D show a correlation matrix for gene expression (A), a heatmap for tumor type versus gene
expression (B), scatterplots (C and D) for gene versus gene correlations and R2 calculation. Fig 2A depicts a
correlation matrix of genes that were identified as potential reference genes by geNorm and NormFinder algorithms
and previously identified tumor markers (CDK6 and TYMS). High correlations are outlined by red colored squares.
Between CDKN1B, GRB2 and GAPDH as well as between ACTB, SDCBP and RHOA a high correlation was identified.
Low correlations are indicated by blue squares and were found for tumor markers (CDK6 and TYMS) versus reference
gene. Fig 2B displays a heatmap. On the x-axis the potential reference genes and tumor markers CDK6 and TYMS are
shown. On the y-axis the investigated tumor types are depicted. Differential expression was found between tumor
types. Though, the reference genes show a constant expression cluster (either low or high) between the samples
investigated. The tumor markers present with differential expression between all samples without showing a specific
cluster. Fig 2C and 2D are exemplary scatterplots of gene versus gene correlation, which were created to calculate the
coefficient of determination (R2). Fig 2C depicts the highest correlation identified (R2 = 0.88) between two potential
reference genes (ACTB and SDCBP). In D, the weakest correlation is depicted, which was found between the two
tumor markers (CDK6 and TYMS).
doi:10.1371/journal.pone.0165181.g002
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Table 1. Summarizes coefficients of correlation (R-squared) for tested genes and top-10 correlations
are highlighted in white.
Ranking Gene A Gene B R-squared
1 ACTB SDCBP 0.88
2 GRB2 RHOA 0.84
3 ACTB GRB2 0.84
4 GRB2 SDCBP 0.82
5 ACTB RHOA 0.81
6 RHOA SDCBP 0.8
7 GRB2 PNN 0.8
8 GAPDH GRB2 0.79
9 GAPDH RHOA 0.78
10 GAPDH CDKN1B 0.77
11 CDKN1B GRB2 0.76
12 CDKN1B PNN 0.74
13 GAPDH PNN 0.72
14 CDKN1B RHOA 0.71
15 ACTB CDKN1B 0.66
16 GAPDH CDK6 0.66
17 ACTB GAPDH 0.63
18 CDKN1B SDCBP 0.63
19 ACTB PNN 0.6
20 RHOA CDK6 0.59
21 PNN RHOA 0.58
22 ACTB LDHB 0.53
23 PNN SDCBP 0.53
24 GAPDH SDCBP 0.52
25 GRB2 CDK6 0.48
26 GRB2 LDHB 0.44
27 LDHB SDCBP 0.43
28 LDHB PNN 0.38
29 ACTB CDK6 0.36
30 PNN CDK6 0.36
31 CDKN1B CDK6 0.34
32 PNN TYMS 0.34
33 CDKN1B LDHB 0.29
34 LDHB RHOA 0.28
35 LDHB TYMS 0.26
36 GAPDH LDHB 0.25
37 SDCBP CDK6 0.25
38 CDKN1B TYMS 0.11
39 GRB2 TYMS 0.09
40 GAPDH TYMS 0.07
41 LDHB CDK6 0.04
42 ACTB TYMS 0.03
43 SDCBP TYMS 0.01
44 CDK6 TYMS 0
45 RHOA TYMS 0
doi:10.1371/journal.pone.0165181.t001
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Alternative quantification/normalizationmethods are under discussion including standard-
ization to cell number and RNA mass quantification (most frequently used in Northern Blot
analysis), but these methods are hardly applicable for clinical samples with low RNA quality
and unknown cell content [9]. Therefore, normalization to reference genes seems to be the best
choice for quantitative mRNA analysis until alternative approaches are found. In the present
study, ACTB, CDKN1B,GAPDH, GRB2, RHOA and SDCBPwere identified as suitable refer-
ence genes in neuroendocrine tumors of the lung.
Based on the presented choice of reference genes, we have identified diagnostic, prognostic
and therapy-relevant biomarkers in NELC.With respect to apoptosis and cell cycle, NELC
show a distinct expression and mutation pattern. Carcinoids use CDK4/6 and CCND1 to drive
cell cycle progression by controlling RB1 phosphorylation.On the other hand, carcinomas con-
trol this signaling cascade by using the opposite way (CDK2 and CCNE1) [15]. Of note, TP53
mutations are exclusively found in carcinomas, but not in carcinoids [19] and on the miRNA
level NELC subtypes showed significantly different expression of miRNAs regulating prolifera-
tion and apoptosis [20].
Besides, our results revealed why the large randomized phase III clinical trial GALES (global
analysis of pemetrexed in SCLC extensive stage) failed. Low expression of FOLR1 and FPGS,
but high expression of TYMS is the predominant phenotype found in SCLC rendering peme-
trexed therapy useless in this entity [14]. Similar results were found in squamous cell carci-
noma of the lung where high expression of TYMS precludes response to pemetrexed [21].
Furthermore, poor outcome correlated with elevated expression of the transcription factors
SOX11 and PAX6 [16]. Mediators of angiogenesis (HIF1A,CRHR2,KDR and FIGF) correlated
with decreased progression-free survival, poor outcome and more aggressive clinical behavior
of NELC revealing potential therapy targets for tyrosine-kinase inhibitors and antibodies [7].
Another potent therapy target could be the 26S proteasome, because it showed significantly
higher expression in NELC than in benign controls [22]. Several potent proteasome inhibitors
are currently tested in clinical phase trials or have received clinical clearance [23].
Conclusion
FFPE-derivedmRNA can be reliably used for expression analysis using the nCounter technol-
ogy (NanoString). The method uses two specific oligo-probes, which hybridize to ~100 nt in
the region of interest, enabling the analysis of the highly degraded nucleic acids.ACTB,
CDKN1B,GAPDH, GRB2, RHOA and SDCBPwere identified as constantly expressed genes
with high stability (M-)values according to geNorm and NormFinder and coefficients of corre-
lation making them suitable reference genes for expression analysis/biological normalization in
neuroendocrine tumors of the lung.
Supporting Information
S1 Fig. Boxplots for gene expression versus tumor subtype. S1 Fig shows boxplots for gene
expression of potential reference genes, which were identified by either geNorm or NormFin-
der algorithm, in correlation with the four investigated tumor subtypes. On the x-axis the four
investigated tumor subtypes are shown. The y-axis depicts the mRNA counts for each gene. A
Kruskal-Wallis test was performed and significantly differential expression is outlined by p-val-
ues. In most cases, atypical carcinoids showed much lower expression than the other three enti-
ties. Also SCLC showed relatively low counts.
(PDF)
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S2 Fig. Scatterplots and coefficientsof correlation for gene versus gene correlations. S2 Fig
depicts scatterplots and the coefficient of correlation for gene versus gene correlation. Potential
reference genes were identified by applying the geNorm and NormFinder algorithm. Potential
reference genes were correlated and the coefficient of determination (R2) was calculated to
identify the conformity between them. As control, tumor markers (CDK6 and TYMS) were
included in the analysis and showed very low correlation with the potential reference genes.
(PDF)
S1 Table. The gene name, gene ID and properties of the custom CodeSet that was used for
the nCounter analysis.
(XLS)
S2 Table. Patient data, RNA concentration and quality (RIN) and exemplarily gene mRNA
counts.
(XLSX)
S3 Table. Summarizes gene names, calculated stability values by NormFinder or geNorm
algorithm,mean and medianmRNA counts per gene.Grey stained rows indicate genes that
show mean and/or median expression of>500 mRNA counts. Median for all genes is 99
counts and mean for all genes is 1,132 counts.
(XLSX)
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